2022
Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, Justice AC, Napravnik S, Edwards JK, Browne LE, Agil DM, Silverberg MJ, Skarbinski J, Leyden WA, Stewart C, Hogan BC, Gebo KA, Marconi VC, Williams CF, Althoff KN. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open 2022, 5: e2236397. PMID: 36227594, PMCID: PMC9561947, DOI: 10.1001/jamanetworkopen.2022.36397.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCohort StudiesCOVID-19COVID-19 VaccinesFemaleHIV InfectionsHumansMaleSARS-CoV-2ConceptsBreakthrough COVID-19Breakthrough infectionsHIV statusCohort studySevere illnessMAIN OUTCOMEBreakthrough SARS-CoV-2 infectionCOVID-19 vaccine typesLow CD4 cell countsSARS-CoV-2 infectionCOVID-19Severe immune suppressionCD4 cell countProportion of patientsCells/μLPrevious COVID-19Additional vaccine dosesProportional hazards modelDiscrete-time proportional hazards modelsRisk reduction recommendationsVaccine guidelinesCD4 cellsCumulative incidenceHazard ratioClinical factors
2020
Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)
Ong SY, Chui P, Bhargava A, Justice A, Hauser RG. Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System). The American Journal Of Cardiology 2020, 137: 25-30. PMID: 32991852, DOI: 10.1016/j.amjcard.2020.09.042.Peer-Reviewed Original ResearchConceptsLow-dose aspirinElectronic health recordsSelf-reported useEHR dataPatients' self-reported useLow-dose aspirin useAtherosclerotic cardiovascular diseaseAmerican Heart AssociationEHR recordsNon-specific terminologyAspirin usePrimary preventionHeart AssociationCardiovascular diseaseAmerican CollegeAspirinPatientsHealth recordsEHR implementationEHR searchesImplementable guidelinesGuidelinesRecordsDiseaseCardiology
2019
Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Achenbach CJ, Hessol NA, D'Souza G, Gebo KA, Gill MJ, Grover S, Horberg MA, Li J, Mathews WC, Mayor AM, Park LS, Rabkin CS, Salters K, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R, AIDS N, Betts A, Brooks J, Freeman A, Van Rompaey S, Burchell A, Yip B, You B, Hogan B, Grasso C, Hogg R, Benson C, Drozd D, Sterling T, Haas D, Humes E, Crane H, Willig J, Eron J, Martin J, Saag M, Jing J, Zhang J, Lindsay J, Hunter-Mellado R, Deeks S, Zhu J, Montaner J, McReynolds J, Gabler K, Buchacz K, Rodriguez B, Thorne J, Margolick J, Anastos K, Jacobson L, Klein M, Kroch A, Morton L, Turner M, Fiellin D, Gange S, Mugavero M, Harrigan P, Rebeiro P, Bosch R, Kirk G, Mayer K, McKaig R, Coburn S, Napravnik S, Kitahata M, Lober W, Lee J. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. The Lancet HIV 2019, 6: e240-e249. PMID: 30826282, PMCID: PMC6531288, DOI: 10.1016/s2352-3018(18)30360-6.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaRecent CD4 countCD4 countHIV viraemiaKey independent predictorsViral loadIndependent predictorsNorth American AIDS Cohort CollaborationCNS non-Hodgkin's lymphomaOverall non-Hodgkin lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaAssociation of immunosuppressionMulticentre cohort studyNon-Hodgkin lymphoma (NHL) riskAverage viral loadUS Health ResourcesB-cell lymphomaOverall immune functionB cell activationLong-term careCohort CollaborationRecent immunosuppressionAntiretroviral therapyCohort studyContributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies
Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, Re V, Sterling TR, Desir FA, Lichtenstein K, Willig J, Rachlis AR, Kirk GD, Anastos K, Palella FJ, Thorne JE, Eron J, Jacobson LP, Napravnik S, Achenbach C, Mayor AM, Patel P, Buchacz K, Jing Y, Gange SJ, Research and Design N. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. The Lancet HIV 2019, 6: e93-e104. PMID: 30683625, PMCID: PMC6589140, DOI: 10.1016/s2352-3018(18)30295-9.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseEnd-stage renal disease outcomesPopulation attributable fractionRenal disease outcomesTraditional risk factorsElevated total cholesterolLiver diseaseMyocardial infarctionRisk factorsRenal diseaseTotal cholesterolDisease outcomeHIV RNANorth American AIDS Cohort CollaborationDetectable plasma HIV RNALow CD4 cell countsHepatitis B virus infectionEnd-stage renal diseaseClinical AIDS diagnosisDetectable HIV RNAHIV Clinical CohortLow CD4 countCD4 cell countPlasma HIV RNAB virus infection
2018
HIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers
Farhadian S, Jalbert E, Deng Y, Goetz MB, Park LS, Justice A, Dubrow R, Emu B. HIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 337-344. PMID: 29140874, PMCID: PMC5807137, DOI: 10.1097/qai.0000000000001595.Peer-Reviewed Original ResearchConceptsCD8 T cellsT-cell markersCD4 T cellsHIV infectionT cellsAntiretroviral therapyEffector memory CD4 T cellsImmune systemVeterans Aging Cohort StudyMemory CD4 T cellsNaive CD4 T cellsAging Cohort StudyT cell subsetsT-cell phenotypeCopies/mLCross-sectional studyRace/ethnicityChronic HIVUninfected subjectsUninfected menCohort studyHIV diseaseHigher proportionHIV serostatusHIV status
2017
Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries
Youn B, Shireman TI, Lee Y, Galárraga O, Rana AI, Justice AC, Wilson IB. Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries. AIDS 2017, 31: 1697-1707. PMID: 28700393, PMCID: PMC5625296, DOI: 10.1097/qad.0000000000001541.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersII receptor blockersHIV patientsControl medicationTherapy persistenceReceptor blockersEnzyme inhibitors/angiotensin II receptor blockersCox proportional hazards modelNon-HIV medicationsUS Medicaid beneficiariesHIV-negative controlsRetrospective cohort studyKaplan-Meier curvesDuration of treatmentProportional hazards modelTen-year trendsSecular trendsART initiatorsCohort studyHazard ratioMedian timeFill dateMedicaid claimsMedicaid beneficiariesAdjusted modelCD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte A, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Vehreschild J, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases 2017, 65: 959-966. PMID: 28903507, PMCID: PMC5850630, DOI: 10.1093/cid/cix466.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioCD8 countsCD8 ratioCohort CollaborationAntiretroviral therapyCause mortalityCD4 countHazard ratioMiddle tertilePrognostic markerAIDS mortalityCause-specific mortality hazard ratiosAntiretroviral Therapy Cohort CollaborationHigher CD4 countsMortality hazard ratioCells/μLHuman immunodeficiency virusIndependent prognostic markerNorth American cohortAssociation of CD8Shape of associationsAssociation of CD4Immunodeficiency virusHuman immunodeficiencyCD4Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survivalComparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study
Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA, Collaboration H, Systems C. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. The Lancet HIV 2017, 4: e251-e259. PMID: 28411091, PMCID: PMC5492888, DOI: 10.1016/s2352-3018(17)30043-7.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsVirological failureHazard ratioCell countViral loadRisk ratioObservational studyTime-varying CD4 cell countHIV RNA viral loadAntiretroviral therapy regimenCombination antiretroviral therapyRNA viral loadAIDS Research NetworkMortality hazard ratioIntegrated Clinical SystemsHIV-CAUSAL CollaborationLong-term safetyCell count differencesAntiretroviral therapyCD4 countTherapy regimenProspective studyImmunological outcomesClinical guidelines
2016
Incidence of Mental Health Diagnoses in Veterans of Operations Iraqi Freedom, Enduring Freedom, and New Dawn, 2001-2014.
Ramsey C, Dziura J, Justice AC, Altalib HH, Bathulapalli H, Burg M, Decker S, Driscoll M, Goulet J, Haskell S, Kulas J, Wang KH, Mattocks K, Brandt C. Incidence of Mental Health Diagnoses in Veterans of Operations Iraqi Freedom, Enduring Freedom, and New Dawn, 2001-2014. American Journal Of Public Health 2016, 107: 329-335. PMID: 27997229, PMCID: PMC5227942, DOI: 10.2105/ajph.2016.303574.Peer-Reviewed Original ResearchConceptsMental health diagnosesMajor depressive disorderPosttraumatic stress disorderHealth diagnosisIncidence rateDrug use disorder diagnosisIncident posttraumatic stress disorderOperation Iraqi FreedomAge 18Veterans Health Administration electronic health recordsDisorder diagnosisIncident bipolar disorderHigh-risk groupSociodemographic risk factorsAlcohol use disorder diagnosisMental health conditionsEnduring FreedomIraqi FreedomRace/ethnicityElectronic health recordsIncident schizophreniaRisk factorsDepressive disorderAge 45MDD diagnosisEstimating healthcare mobility in the Veterans Affairs Healthcare System
Wang KH, Goulet JL, Carroll CM, Skanderson M, Fodeh S, Erdos J, Womack JA, Abel EA, Bathulapalli H, Justice AC, Nunez-Smith M, Brandt CA. Estimating healthcare mobility in the Veterans Affairs Healthcare System. BMC Health Services Research 2016, 16: 609. PMID: 27769221, PMCID: PMC5075153, DOI: 10.1186/s12913-016-1841-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overDelivery of Health CareElectronic Health RecordsEmigration and ImmigrationFemaleHospitals, VeteransHumansMaleMental DisordersMiddle AgedPatient Acceptance of Health CareRetrospective StudiesUnited StatesUnited States Department of Veterans AffairsVeteransVeterans HealthYoung AdultConceptsHealthcare systemVeterans Health Administration electronic health recordsVeterans Affairs Healthcare SystemHealthcare mobilityRetrospective cohort studyHepatitis C virusOutcomes of careDifferent healthcare systemsDistinct healthcare systemsElectronic health recordsClinical characteristicsCohort studyHealthcare utilizationC virusSpecialty carePsychiatric disordersYounger veteransDisease preventionYounger agePopulation healthHealth recordsVeteransStatus changesCareYear periodCause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy
Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne JA, Collaboration A. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLOS ONE 2016, 11: e0160460. PMID: 27525413, PMCID: PMC4985160, DOI: 10.1371/journal.pone.0160460.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyLow CD4 countHIV-positive patientsAntiretroviral therapyCD4 countDrug useAntiretroviral Therapy Cohort CollaborationFive-year mortality riskAIDS infectionOlder ageCause-specific mortality rate ratiosNon-AIDS cancerLiver-related mortalityHIV Cohort StudyInjection drug useHIV-1 RNAMortality rate ratiosLiver-related diseasesHigh subsequent mortalityCohort CollaborationLow CD4Prior AIDSCardiovascular mortalityCohort studyPrognostic factorsMortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JAC, Collaboration F, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases 2016, 62: 1571-1577. PMID: 27025828, PMCID: PMC4885653, DOI: 10.1093/cid/ciw183.Peer-Reviewed Original ResearchConceptsStart of ARTMortality rate ratiosCombination antiretroviral therapyAntiretroviral therapyMortality of patientsCD4 countMortality rateLow baseline CD4 countYears of ARTBaseline CD4 countHigher baseline CD4Collaborative Cohort StudyStart of treatmentNorth American cohortStrong inverse associationLong-term survivalShort-term survivalBaseline CD4CD4 groupCohort studyInverse associationPatientsAmerican cohortYears durationMortality
2015
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete dataBoosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries
Cain L, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins J, Sterne J, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende M, Abgrall S, Costagliola D, Hernán M. Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases 2015, 60: 1262-1268. PMID: 25567330, PMCID: PMC4447777, DOI: 10.1093/cid/ciu1167.Peer-Reviewed Original ResearchConceptsAtazanavir regimenVirologic failureProspective studyNucleoside reverse transcriptase inhibitor (NRTI) backboneFirst-line antiretroviral regimensReverse transcriptase inhibitor backboneAIDS-free individualsTreat hazard ratiosCD4 cell countCurrent clinical guidelinesHuman immunodeficiency virusRandomized clinical trialsAdjusted intentionAntiretroviral regimensAtazanavir groupBoosted atazanavirContaining RegimensVirologic outcomesCD4 countNRTI backboneHazard ratioClinical outcomesImmunodeficiency virusClinical guidelinesClinical trials
2014
End-Stage Renal Disease Among HIV-Infected Adults in North America
Abraham A, Althoff K, Jing Y, Estrella M, Kitahata M, Wester C, Bosch R, Crane H, Eron J, Gill M, Horberg M, Justice A, Klein M, Mayor A, Moore R, Palella F, Parikh C, Silverberg M, Golub E, Jacobson L, Napravnik S, Lucas G, AIDS F, Kirk G, Benson C, Bosch R, Collier A, Boswell S, Grasso C, Mayer K, Hogg R, Harrigan R, Montaner J, Cescon A, Brooks J, Buchacz K, Gebo K, Moore R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Goedert J, Jacobson L, Klein M, Rourke S, Burchell A, Rachlis A, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Justice A, Dubrow R, Fiellin D, Sterling T, Haas D, Bebawy S, Turner M, Gange S, Anastos K, Moore R, Saag M, Gange S, Althoff K, Kitahata M, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Webster E, Morton L, Simon B, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Hanna D, Rebeiro P, Wong C, Mendes A. End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases 2014, 60: 941-949. PMID: 25409471, PMCID: PMC4357817, DOI: 10.1093/cid/ciu919.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseSex-standardized incidence ratiosRisk of ESRDDiabetes mellitusESRD casesBlack racePredictors of ESRDNorth American AIDS Cohort CollaborationHepatitis C virus coinfectionC virus coinfectionESRD risk factorsIncident ESRD casesHuman immunodeficiency virusHigh viral loadMajority of casesCohort CollaborationVirologic suppressionESRD incidencePrior AIDSRenal transplantViral suppressionInject drugsRenal diseaseVirus coinfectionBlack patients
2013
Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States
Collaboration T, del Amo J, Jarrin I, May M, Dabis F, Crane H, Podzamczer D, Sterling T, Abgrall S, Lampe F, Justice A, Castagna A, Boesecke C, Staehelin C, De Wolf F, Guest J, Mugavero M, Khaykin P, Samji H, Ingle S, Sterne J, Gill M. Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. Clinical Infectious Diseases 2013, 56: 1800-1809. PMID: 23457077, DOI: 10.1093/cid/cit111.Peer-Reviewed Original ResearchConceptsAdjusted mortality hazard ratioAntiretroviral therapyCause mortalityHazard ratioAIDS mortalityHuman immunodeficiency virus-positive subjectsLower mortalityNon-AIDS mortalityAfrican AmericansMortality hazard ratioVirus-positive subjectsAIDS mortality ratesCanadian First Nations peopleFirst Nations peopleCohort studyUS patientsCox regressionEuropean patientsHealthy migrantMortality ratePatientsHigh mortalityMortalityEthnicity/raceDeath rate
2012
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics
May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, Monforte A, Vehreschild JJ, Sterne J, Collaboration T. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal Of Epidemiology 2012, 41: 1807-1820. PMID: 23148105, PMCID: PMC3535877, DOI: 10.1093/ije/dys164.Peer-Reviewed Original ResearchConceptsCompleteness of ascertainmentHIV-positive patientsAntiretroviral therapyMortality rateAdult HIV-positive patientsPrevious AIDS diagnosisRates of AIDSAdjusted mortality rateMortality rate ratiosHigher mortality riskHigh mortality rateDiverse patient cohortCohort heterogeneityCohort CollaborationPatient characteristicsHIV treatmentAIDS diagnosisPatient cohortAdjusted ratesClinical careMortality riskCohort characteristicsPatientsDeath ascertainmentCohortU.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.
Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin J, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Brooks JT. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Annals Of Internal Medicine 2012, 157: 325-35. PMID: 22944874, PMCID: PMC3534765, DOI: 10.7326/0003-4819-157-5-201209040-00005.Peer-Reviewed Original ResearchConceptsCD4 cell countCD4 T-lymphocyte cell countMedian CD4 cell countT-lymphocyte cell countAntiretroviral therapy useHIV VLCell countNA-ACCORDHIV RNATherapy useViral loadU.S. National HIV/AIDS StrategyHealth outcomesNational HIV/AIDS StrategyCanadian HIV Trials NetworkHIV/AIDS StrategyActive antiretroviral therapyHIV outpatient clinicAnnual cross-sectional analysesHIV Cohort StudyProportion of participantsNational surveillance systemRelated health outcomesSimilar demographic characteristicsCross-sectional analysisComorbid Diabetes and the Risk of Progressive Chronic Kidney Disease in HIV-Infected Adults
Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, Rimland D, Rodriguez-Barradas MC, Chang CC, Justice AC, He JC, Wyatt CM. Comorbid Diabetes and the Risk of Progressive Chronic Kidney Disease in HIV-Infected Adults. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2012, 60: 393-399. PMID: 22592587, PMCID: PMC3392432, DOI: 10.1097/qai.0b013e31825b70d9.Peer-Reviewed Original ResearchConceptsCKD risk factorsTraditional CKD risk factorsRisk factorsBaseline eGFRChronic kidney disease progressionProgressive chronic kidney diseaseChronic kidney diseaseKidney disease progressionGlomerular filtration rateMean baseline eGFRRisk of CKDRate of progressionCox proportional hazardsVeterans Healthcare AdministrationUse of cARTBaseline HIVCKD progressionComorbid diabetesAdjunctive therapyDiabetes statusGlycemic controlKidney diseaseProgressive CKDComplex comorbiditiesFiltration rate